According to Siemens Healthineers, the manufacturer of the device, the Food and Drug Administration (FDA) has granted 510(k) approval for the Symbia Pro.specta™ SPECT/CT scanner.
Siemens Healthineers launched the device at the 2022 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting and said the single-photon-emission computed tomography/computed tomography (SPECT/CT) system offers advanced imaging technology. Key benefits include automated SPECT motion correction and the ability to obtain up to 64 slices of low-dose CT to facilitate detailed image quality, the company said.
In addition to optimal imaging at low doses, Siemens Healthineers noted that the Symbia Pro.specta™ SPECT/CT scanner offers myExam Companion, which provides automated workflow guidance. The company adds that clinicians will also have access to the device’s custom clinical tools designed to ensure optimal imaging with cardiology, neurology, oncology and orthopedic applications.
Siemens Healthineers noted that the Symbia Pro.specta™ SPECT/CT scanner will provide greater accessibility, noting that it should fit into most existing SPECT spaces and is designed to support the Symbia Intevo™ line of SPECT/ replace CT scanners.
“Siemens Healthineers is proud to introduce the Symbia Pro.specta SPECT/CT scanner, providing our customers with the ideal vehicle for the transition from their SPECT-only and first-generation SPECT/CT cameras to a state-of-the-art SPECT camera. /CT scanner capable of performing a full spectrum of nuclear medicine studies,” said Jim Williams, Ph.D., head of Siemens Healthineers Molecular Imaging. “The Symbia Pro.specta will help healthcare facilities overcome barriers to care by ensuring accessibility through its ease of use and the ability to fit into existing SPECT rooms.”